Analysts Set BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Price Target at $20.60

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) have been given an average recommendation of “Moderate Buy” by the twelve research firms that are presently covering the firm, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $20.60.

A number of brokerages recently issued reports on BCRX. Citizens Jmp increased their price objective on BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the stock a “market outperform” rating in a report on Thursday, May 7th. Wall Street Zen raised BioCryst Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Saturday, August 8th. Wedbush lowered their price target on BioCryst Pharmaceuticals from $21.00 to $20.00 and set an “outperform” rating on the stock in a report on Thursday, August 6th. Needham & Company LLC reduced their price objective on shares of BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating for the company in a report on Wednesday, May 6th. Finally, Cantor Fitzgerald increased their target price on shares of BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the company an “overweight” rating in a research report on Tuesday, June 30th.

BioCryst Pharmaceuticals Stock Up 0.4%

Shares of NASDAQ BCRX opened at $9.87 on Friday. The firm’s 50-day moving average price is $9.70 and its two-hundred day moving average price is $9.05. BioCryst Pharmaceuticals has a 52-week low of $6.00 and a 52-week high of $11.22. The stock has a market capitalization of $2.52 billion, a P/E ratio of -6.58 and a beta of 0.55.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its earnings results on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share for the quarter, topping the consensus estimate of $0.15 by $0.15. BioCryst Pharmaceuticals had a negative return on equity of 86.89% and a negative net margin of 40.90%.The firm had revenue of $218.25 million for the quarter, compared to analyst estimates of $183.28 million. During the same period last year, the company earned $0.15 earnings per share. The firm’s revenue for the quarter was up 33.6% on a year-over-year basis. As a group, equities research analysts expect that BioCryst Pharmaceuticals will post -2.25 earnings per share for the current year.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of BCRX. Larson Financial Group LLC boosted its position in shares of BioCryst Pharmaceuticals by 1,188.0% during the 4th quarter. Larson Financial Group LLC now owns 3,542 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 3,267 shares in the last quarter. Allworth Financial LP bought a new stake in shares of BioCryst Pharmaceuticals in the 2nd quarter worth approximately $52,000. Focus Partners Wealth bought a new stake in shares of BioCryst Pharmaceuticals in the 3rd quarter worth approximately $77,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of BioCryst Pharmaceuticals by 26.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,231 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 2,115 shares in the last quarter. Finally, Envestnet Portfolio Solutions Inc. acquired a new stake in BioCryst Pharmaceuticals during the fourth quarter valued at approximately $81,000. 85.88% of the stock is currently owned by institutional investors.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.